EDAP TMS Reports Clinical Results at 7 Years

84% of Study Participants Cancer Free With No Additional Treatment; Lower Side Effects Observed in 8 Year Study 


LYON, France, Oct. 31  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), presented advanced clinical data on the success of HIFU with Ablatherm(R) at the ISTU congress held at Harvard Medical School in Boston, MA.

The 5th International Symposium on Therapeutic Ultrasound (ISTU) was held in the Conference Center at Harvard Medical School.  Its goals, both scientific and educational, are to assess the current state-of-the-art in therapeutic ultrasound, to foster communication among diverse multidisciplinary fields, to identify key problems and their solutions, to provide an overview and basic background for clinical uses of ultrasound therapy, and to share insights among researchers, clinical users and device manufacturers.

ISTU confirmed that several thousand patients with tumors of varying pathologies have been treated with therapeutic ultrasound in recent years. Recent advances in medical imaging and ultrasound technology with high intensity focused ultrasound (HIFU) coupled with increased interest in minimally invasive medicine are expected to continue the rapid advance of this technology in the coming years.

EDAP is broadly recognized as one of the leading companies worldwide in this field.  The company's presence at the ISTU conference further confirmed its position with heavy traffic at its booth.  Additionally, the company presented four summaries and papers related to its ongoing treatment success and clinical advances related to the field of localized prostate cancer.

Ablatherm users presented the latest clinical results obtained using EDAP's Ablatherm HIFU technology for the treatment of prostate cancer.  Dr. Stefan Thuroff, from Harlaching Hospital, Munich, Germany, presented a follow- up study of more than 1,000 patients treated with Ablatherm.  The results showed a success rate up to 93.7% based on negative biopsies and a Nadir PSA down to 0 for low and intermediate risk patients.  These results were achieved just two months post treatment, a significant improvement in the time to confirmable results as compared to other therapies.  Additionally, the results indicate that 70% of the patients who opted for partial ablation of the prostate remained potent, once again well above the normal ranges of other therapies.

In a different presentation detailing the side effects related to HIFU with a follow up at 8 years and a population of 1,200 patients Prof. C. Chaussy, also of Munich, demonstrated Ablatherm HIFU proved to have low occurrences of short and medium range side effects.  The observed incidences were more comparable to side effects seen in treating enlargement of the prostate through TURP as opposed to the more severe side effects expected in treating prostate cancer.

Dr. Albert Gelet, from Edouard Herriot Hospital, Lyon, France, further validated the success rates of HIFU.  His presentation, based on a study on 124 patients treated with Ablatherm, reported a cancer free rate of 84% at 7 years without additional therapy.

Hugues de Bantel, CEO of EDAP, commented: "The ISTU meeting at Harvard Medical School provided EDAP with a unique opportunity to reinforce our position as one of the leading research and clinical teams in HIFU therapies worldwide.  We are particularly pleased with the quality of the presentations made by our practitioners who are well regarded within their respective professional communities.  With these presentations, EDAP clearly continues to advance its worldwide leadership position in HIFU treatment for localized prostate cancer as evidenced by the significant results achieved at ever longer follow up, the number of centers utilizing Ablatherm HIFU, the now more than 8,400 patients treated, and quality of results with our device compared to other participants in this field."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets the Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer.  HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects.  The company is also developing this technology for the treatment of certain other types of tumors.  EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by phone at [phone] or see the Company's Web site at: http://www.edap-tms.com/ .

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties.  These include statements regarding the Company's growth and expansion plans.  Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements.  Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.

   CONTACT:  EDAP TMS S.A.
             Hugues de Bantel - Philippe Chauveau
             Blandine Confort
             [phone]

             Halliburton Investor Relations
             Matt Kreps - Geralyn DeBusk
             972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau or Blandine Confort, all of

EDAP TMS S.A., [phone]; or Matt Kreps or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/ 

Copyright